Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan

Cat. No.: HY-145399

CAS No.: 2495742-34-0

Molecular Formula: $C_{57}H_{77}N_7O_{18}$

Molecular Weight: 1148.26

Target: Drug-Linker Conjugates for ADC; Topoisomerase

Pathway: Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Storage: -20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (174.18 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.8709 mL	4.3544 mL	8.7088 mL
	5 mM	0.1742 mL	0.8709 mL	1.7418 mL
	10 mM	0.0871 mL	0.4354 mL	0.8709 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a Drug-Linker Conjugates for ADC, which comprises a topoisomerase inhibitor and a linker for ligand unit connecting. Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan can be used to synthesis antibody-drug conjugate (ADC)[1].

IC_{50} & Target

Camptothecins

REFERENCES

[1]. Schmidt, et al. Computer-based scoring method indicating a cancer patient's response to an anti-B7H4 antibody-drug conjugate therapy using a convolutional neural network, WO2022053685, 2022.

[2]. Philip Wilson Howard, et al. Compounds and conjugates thereof. Patent US20200306243A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA